Jacqueline Barrientos, MD, discusses the importance of understanding treatment failure in CLL patients, and what options are available. She provides details of a current trial comparing two treatments that work on different pathways (PI3K and BTK B-cell inhibitors), with the goal of understanding the best salvage options following treatment failure.